n CME : Your SA Journal of CPD - Selection of oral agents in the management of type 2 diabetes : main topic

Volume 21, Issue 10
  • ISSN : 0256-2170



Type 2 diabetes is a heterogeneous condition characterised by varying degrees of both insulin resistance and insulin deficiency (due to pancreatic ß-cell dysfunction). <br>Type 2 diabetes is a progressive disease, with continued deterioration in ß-cell function occurring in the majority of affected persons. <br>Oral antihyperglycaemic therapy is adjunctive to diet, exercise and lifestyle management. <br>Five classes of oral antihyperglycaemic agents are available for clinical use in South Africa, each with specific advantages and disadvantages and broadly designated as 'secretagogues' and 'sensitisers'. <br>Attempting to match therapy (based on mechanism of action of the pharmacological agent) with perceived pathophysiology is a logical approach to a complex metabolic disorder, but continued surveillance of metabolic control and adjustment in doses are usual. <br>Combination therapy is needed in the majority of persons with type 2 diabetes. <br>Insulin therapy is a reality for most persons with type 2 diabetes, if metabolic targets are to be attained and maintained.

Loading full text...

Full text loading...


Article metrics loading...


This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error